GSK's Avandia woes spark talk of cuts

Share this article:
UK drugmaker GlaxoSmithKline is eyeing cuts to its sales force in response to declining sales of its type 2 diabetes drug Avandia.

According to a report in The Times of London, Britain's largest drug company is considering a change of marketing strategy that could involve letting go or redeploying staff involved in the sale of the embattled drug.

GSK's global sales force is comprised of 30,000 people globally, with 9,000 in US.

Some analysts have predicted that GSK will try to redeploy sales force members wherever possible, rather than downsize—a move that would be in contrast to the cuts made by rivals Pfizer and AstraZeneca recently.

In July, Federal advisors recommended keeping Avandia on the market but said its label should include strict warnings on use. While not the worst outcome for GSK, the warnings could accelerate the drug company's slide in terms of share in the peroxisome proliferator-activated receptor (PPAR) drug market.

Debate over the drug grew after a New England Journal of Medicine meta-analysis in May linked Avandia to an increased risk of heart attack. The analysis was conducted by prominent Cleveland Clinic cardiologist Steven Nissen.  Avandia had sales of approximately $2.2 billion.

Share this article:

Email Newsletters

More in News

BI rethinks hepatitis business, posts 2013 results

BI rethinks hepatitis business, posts 2013 results

Boehringer Ingelheim says it is no longer pursuing an interferon-free combination of faldaprevir and deleobuvir.

Roche wraps quarter with two fewer pipeline medications

Roche wraps quarter with two fewer pipeline medications

Roche also announced first-quarter sales shrank 1%.

2013 favored specialists, specialty Rx

2013 favored specialists, specialty Rx

The latest IMS Institute for Healthcare Informatics assessment of 2013's prescription drug use shows that 2.3% of prescriptions account for 30% of a patient's out-of-pocket prescription costs.